Fortress Biotech, Inc. (FBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, FBIO trades at $2.65 with a market cap of $82.38M and a P/E ratio of 0.69. FBIO moved +4.74% today. Year to date, FBIO is -37.94%; over the trailing twelve months it is +51.43%. Its 52-week range spans $1.33 to $4.53. Analyst consensus is buy with an average price target of $10.75. Rallies surfaces FBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Journey Medical Expands Emrosi Access to Over 150 Million Commercial Lives: Journey Medical secured a contract with a third major GPO, expanding Emrosi payer access from approximately 100 million to over 150 million commercial lives as of April 1, 2026. This milestone raises U.S. commercial coverage to about 85%, positioning the brand for increased prescription demand and improved profitability.
| Metric | Value |
|---|---|
| Price | $2.65 |
| Market Cap | $82.38M |
| P/E Ratio | 0.69 |
| EPS | $3.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.53 |
| 52-Week Low | $1.33 |
| Volume | 1.58K |
| Avg Volume | 0 |
| Revenue (TTM) | $66.16M |
| Net Income | $128.94M |
| Gross Margin | 66.22% |
2 analysts cover FBIO: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.75.